Skip to content
Government Federal, Medical Health Aged Care

Sepsis burden grows, but early signs of progress

ACSQHC 2 mins read

10 September 2025

A landmark report released ahead of World Sepsis Day, 13 September 2025, reveals that sepsis is more prevalent, deadly and costly than previously understood – prompting renewed calls to improve early detection, data quality and clinical care across the healthcare system.

Published by the Australian Commission on Safety and Quality in Health Care (the Commission), the Sepsis Epidemiology Report analysed over 900,000 sepsis-related hospitalisations in Australian public hospitals from 2013–14 to 2022–23.

In 2022–23 alone, there were over 84,000 sepsis hospitalisations and more than 936,000 hospitalisations over the 10-year reporting period. This is significantly greater than the previous estimate of 55,000 people affected each year.

Conjoint Professor Carolyn Hullick, Chief Medical Officer of the Commission and Emergency Physician, said the findings are a call to action.

“Sepsis is a time-critical emergency. Our report shows that many Australians face not only a high risk of death, but also long recovery periods and repeat hospitalisations. We must do more to reduce the impact of sepsis on health services and improve patient outcomes and support health services in early recognition, treatment and discharge planning,” Conjoint Professor Hullick said.

The report also provides important insights into a range of health and social determinant risk factors. 2022–23 figures show:

·        1 in 3 people hospitalised for sepsis also had diabetes

·        1 in 6 had renal (kidney) disease

·        Sepsis hospitalisation rates for Aboriginal and Torres Strait Islander people were double that of non-indigenous people

·        Higher risk of readmission linked to rural location and socioeconomic disadvantage.

“The link between complex chronic illness, socioeconomic disadvantage and higher rates of sepsis must shape how we deliver care. This data gives us a clearer picture of who is most at risk and how to intervene earlier,” said Conjoint Professor Hullick.

This report also found a promising sign of progress, with a decline in the proportion of sepsis-related deaths occurring in emergency departments. This suggests a growing impact from sepsis clinical pathways and education.

The Commission’s new report builds on work under the National Sepsis Program and supports the development of a National Sepsis Data Plan to improve consistency in coding and documentation.

The full report is now available on the Commission’s website at: safetyandquality.gov.au/sepsis-report

 

Media enquiries

Michelle Boland, Senior Communications Officer

E: [email protected] M: 0413 782 111

 

About the Commission

The Australian Commission on Safety and Quality in Health Care leads and coordinates national improvements in the safety and quality of health care based on the best available evidence. By working in partnership with patients, carers, clinicians, the Australian, state and territory health systems, the private sector, managers and healthcare organisations, the Commission aims to ensure that the health system is better informed, supported and organised to deliver safe and high-quality care. safetyandquality.gov.au

Media

More from this category

  • Medical Health Aged Care
  • 18/03/2026
  • 18:41
Samsung Bioepis Co., Ltd.

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology   INCHEON, Korea--BUSINESS WIRE-- Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The…

  • Contains:
  • Medical Health Aged Care
  • 18/03/2026
  • 16:49
Palliative Care Australia

Better end-of-life care for older Australians must be the next step in aged care reform

Palliative Care Australia this week brought leaders from aged care, palliative care, health, advocacy, research and policy together in Melbourne for its inauguralPalliative Care…

  • Contains:
  • Government Federal, Legal
  • 18/03/2026
  • 16:12
Law Society of NSW

Vale Sir Anthony Mason

Statement Wednesday, 25 February 2026 Vale Sir Anthony Mason On behalf of the Law Society of NSW, I offer my sincerest condolences to the family and friends of the late Sir Anthony Mason AC KBE GBM KC who passed away last night. Sir Anthony’s remarkable achievements in the law are well known, most notably in his service as Chief Justice of Australia capping his 23 years as a judge of the High Court of Australia. These include the recognition of native title and abandonment of the doctrine of terra nullius in Mabo v Queensland (No2); and the recognition of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.